USP "introductory" patient leaflets
Executive Summary
U.S. Pharmacopeia says it will issue patients' pharmaceutical information leaflets for new drugs within one month after they are approved. Based on FDA-approved physician labeling, the leaflets "are intended to fill an immediate need for information on a temporary basis until a full monograph is developed through USP's consensus process'and added to USP-Dispensing Information, the organization said. The program was approved by USP's Drug Information Division Executive Committee.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth